StockpollyBeta
Get App
Popularity #914
BIIB · NASDAQ · Drug Manufacturers - General

Biogen (BIIB)

Develops neurological medicines spanning MS, rare disease, Alzheimer’s, and complement-mediated conditions.

$225.94
vs last close+6.87 (+3.14%)

  1. Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

    GlobeNewsWire

  2. Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB

    Defense World

  3. Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience

    MarketBeat

  4. Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

    Seeking Alpha

  5. Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

    MarketBeat

  6. Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Seeking AlphaEarnings

  7. Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

    GlobeNewsWireClinical

  8. Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

    GlobeNewsWireClinical

  9. Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease

    GlobeNewsWireClinical

  10. Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?

    Zacks Investment ResearchMarket move

  11. Bank of Nova Scotia Buys Shares of 16,446 Biogen Inc. $BIIB

    Defense WorldOwnership

  12. LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

    GlobeNewsWireProduct

  13. LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

    PRNewsWireProduct

  14. Allworth Financial LP Takes $1.74 Million Position in Biogen Inc. $BIIB

    Defense WorldOwnership

  15. Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

    Defense WorldPrice target

  16. 15,985,736 Shares in Biogen Inc. $BIIB Bought by BlackRock Inc.

    Defense WorldOwnership

  17. Biogen Completes Acquisition of RayThera Inc.

    GlobeNewsWire

  18. Biogen Inc. $BIIB Shares Acquired by Amundi

    Defense World

  19. Why Biogen Stock Topped the Market Today

    The Motley Fool

  20. Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript

    Seeking Alpha